Physicians' Academy for Cardiovascular Education

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

Educational information

This video was recorded at the ESC Heart Failure in Athens, Greece, on May 26, 2019 and is a short reproduction of his presentation during the Late Breaking trial II - Chronic Heart Failure session.


Patrick Rossignol, MD, PhD is nephrologist, professor in Therapeutics and expert in hypertension. He is a physician at the Clinical Investigation Centre Inserm (CIC) at Nancy, France


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Read our summary of the AMBER trial

Share this page with your colleagues and friends: